4.3 Review

Role of β1-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy

Journal

IMMUNOBIOLOGY
Volume 217, Issue 5, Pages 511-520

Publisher

ELSEVIER GMBH
DOI: 10.1016/j.imbio.2011.07.012

Keywords

Autoantibodies; beta(1) receptors; Dilated cardiomyopathy; Pathogenesis; Immunoadsorption

Categories

Ask authors/readers for more resources

Dilated cardiomyopathy (DCM) is a common cause of heart failure. After the identification of several immune regulatory abnormalities in DCM increasing attention has been focused on autoimmune mechanisms as potential key elements in the pathogenesis of the disease. DCM has appeared to be often related to elevated levels of autoantibodies against cardiac structural or functional proteins. Among several autoantibodies (AABs) which react against cardiac cellular proteins that have been detected in sera from DCM patients, those against beta 1-adrenoreceptors (beta 1-ARs) appeared particularly relevant from a pathophysiological point of view. The available experimental and clinical data suggest that in beta 1-AAB-positive patients with DCM the cardiomyopathy might be a beta 1-AR-targeted autoimmune disease. This review summarizes the present knowledge about beta 1-AABs, their role in DCM etiopathogenesis and the therapeutic benefits of beta 1-AAB removal. Special attention is focused on the possible origin of beta 1-AABs, their interaction with the beta(1)-ARs, the prevalence of beta 1-AABs in patients with DCM and the potential pathophysiologic impact of these AABs in the development and progression of the disease. Attention is also given to the amelioration of beta 1-AAB cardiotoxicity by beta(1)-AR antagonists and especially to immunoadsorption (IA) therapy. Responsiveness to IA therapy and its long-term efficiency, as well as post-IA reappearance of beta(1)-AABs and its impact on patients' outcome are also discussed in detail. Finally the important question of whether the therapeutic results of IA are indeed related to beta(1)-AAB removal is analyzed on the basis of available data. Overall the review aims to provide an exhaustive overview of the available experimental and clinical data on beta(1)-AABs in DCM and also a theoretical and practical basis for clinicians who are or intend in future to be engaged in this field. (C) 2011 Published by Elsevier GmbH.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available